The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Department of Pneumology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Pharm Biol. 2022 Dec;60(1):1625-1634. doi: 10.1080/13880209.2022.2110267.
Cusson (Apiaceae) has been used in traditional Asian medicine for thousands of years. Recent studies showed its active compound, osthole, had a good effect on osteoporosis. But there was no comprehensive analysis.
This meta-analysis evaluates the effects of osthole on osteoporotic rats and provides a basis for future clinical studies.
Chinese and English language databases (e.g., PubMed, Web of Science, Cochrane Library, Google Scholar, Embase, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, Weipu Chinese Sci-tech periodical full-text database, and Chinese BioMedical Literature Database) were searched from their establishment to February 2021. The effects of osthole on bone mineral density, osteoclast proliferation, and bone metabolism markers were compared with the effects of control treatments.
To our knowledge, this is the first meta-analysis to evaluate osthole for the treatment of osteoporosis in rats. We included 13 randomized controlled studies conducted on osteoporotic rats. Osthole increased bone mineral density (standardized mean difference [SMD] = 3.08, 95% confidence interval [CI] = 2.08-4.09), the subgroup analysis showed that BMD significantly increased among rats in osthole <10 mg/kg/day and duration of osthole treatment >2 months. Osthole improved histomorphometric parameters and biomechanical parameters, also inhibited osteoclast proliferation and bone metabolism.
Osthole is an effective treatment for osteoporosis. It can promote bone formation and inhibit bone absorption.
独活(伞形科)在亚洲传统医学中已经使用了数千年。最近的研究表明,其活性化合物蛇床子素对骨质疏松症有很好的疗效。但目前还没有全面的分析。
本荟萃分析评估蛇床子素对骨质疏松症大鼠的作用,为今后的临床研究提供依据。
检索了中文和英文数据库(如 PubMed、Web of Science、Cochrane Library、Google Scholar、Embase、中国知网、万方数据知识服务平台、维普中文科技期刊全文数据库和中国生物医学文献数据库),检索时间从建库至 2021 年 2 月。将蛇床子素对骨密度、破骨细胞增殖和骨代谢标志物的影响与对照组进行了比较。
据我们所知,这是首次对蛇床子素治疗大鼠骨质疏松症的荟萃分析。我们纳入了 13 项针对骨质疏松症大鼠的随机对照研究。蛇床子素增加了骨密度(标准化均数差 [SMD] = 3.08,95%置信区间 [CI] = 2.08-4.09),亚组分析显示,蛇床子素 <10 mg/kg/天和蛇床子素治疗时间 >2 个月的大鼠的 BMD 显著增加。蛇床子素改善了组织形态计量学参数和生物力学参数,还抑制了破骨细胞的增殖和骨代谢。
蛇床子素是治疗骨质疏松症的有效药物。它可以促进骨形成,抑制骨吸收。